Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
Mol Ther. 2012 Jun;20(6):1187-95. doi: 10.1038/mt.2012.59. Epub 2012 Apr 3.
Integrating vectors developed on the basis of various retroviruses have demonstrated therapeutic potential following genetic modification of long-lived hematopoietic stem and progenitor cells. Lentiviral vectors (LV) are assumed to circumvent genotoxic events previously observed with γ-retroviral vectors, due to their integration bias to transcription units in comparison to the γ-retroviral preference for promoter regions and CpG islands. However, recently several studies have revealed the potential for gene activation by LV insertions. Here, we report a murine acute B-lymphoblastic leukemia (B-ALL) triggered by insertional gene inactivation. LV integration occurred into the 8th intron of Ebf1, a major regulator of B-lymphopoiesis. Various aberrant splice variants could be detected that involved splice donor and acceptor sites of the lentiviral construct, inducing downregulation of Ebf1 full-length message. The transcriptome signature was compatible with loss of this major determinant of B-cell differentiation, with partial acquisition of myeloid markers, including Csf1r (macrophage colony-stimulating factor (M-CSF) receptor). This was accompanied by receptor phosphorylation and STAT5 activation, both most likely contributing to leukemic progression. Our results highlight the risk of intragenic vector integration to initiate leukemia by inducing haploinsufficiency of a tumor suppressor gene. We propose to address this risk in future vector design.
基于各种逆转录病毒开发的载体在对长寿造血干细胞和祖细胞进行基因修饰后,显示出了治疗潜力。与 γ-逆转录病毒优先选择启动子区域和 CpG 岛不同,慢病毒载体(LV)被认为可以避免 γ-逆转录病毒载体以前观察到的遗传毒性事件,因为它们的整合偏向于转录单元。然而,最近的几项研究表明,LV 插入物有可能激活基因。在这里,我们报告了一种由插入基因失活引发的小鼠急性 B 淋巴细胞白血病(B-ALL)。LV 整合发生在 Ebf1 的第 8 个内含子中,Ebf1 是 B 淋巴细胞发生的主要调节因子。可以检测到各种异常剪接变体,涉及慢病毒构建体的剪接供体和受体位点,导致 Ebf1 全长 mRNA 的下调。转录组特征与该主要 B 细胞分化决定因素的丧失一致,部分获得了髓系标志物,包括 Csf1r(巨噬细胞集落刺激因子(M-CSF)受体)。这伴随着受体磷酸化和 STAT5 激活,这两者都可能有助于白血病的进展。我们的研究结果强调了载体基因内整合通过诱导肿瘤抑制基因的杂合性缺失而引发白血病的风险。我们建议在未来的载体设计中解决这一风险。